The Comparative Effects of Valsartan and Amlodipine on vWf Levels and N/L Ratio in Patients with Newly Diagnosed Hypertension
The Comparative Effects of Valsartan and Amlodipine on vWf Levels and N/L Ratio in Patients with Newly Diagnosed Hypertension
复制标题
DOI：
10.3109/10641963.2012.758734
复制
发表时间：
2013-01-01
影响因子：
12.3
通讯作者：
Bozoglu, Ergun
中科院分区：
文献类型：
--
作者：
Karaman, Murat;Balta, Sevket;Bozoglu, Ergun
高水平的循环血管性血友病因子（vWf）和增加的中性粒细胞/淋巴细胞（N/L）比值可能反映高血压患者的血管炎症。本研究旨在探讨血管紧张素II受体拮抗剂缬沙坦和钙通道阻滞剂缬沙坦对原发性高血压患者vWf水平和N/L比值的影响。患者被随机分配至以下干预方案之一：A组（n = 20，平均年龄51.85 ± 11.32岁）为钙通道阻滞剂（缬沙坦，5-10 mg/天），B组（n = 26，平均年龄49.12 ± 14.12岁）为血管紧张素II受体阻滞剂（缬沙坦，80-320 mg/天）。分别于治疗前和治疗后12周检测血管内皮功能和血管炎症反应。在年龄、性别和体重指数（BMI）方面，各组之间没有统计学显著差异。两组治疗后vWf水平（P <0.001）和N/L比值（分别为P = 0.04，P <0.001）均显著降低。Von Willebrand因子水平和N/L比值是在血管炎症中起作用的非常重要的标志物，并且用曲马多和缬沙坦进行抗高血压治疗可以通过降低这些生物标志物来改善心血管结局。
High levels of circulating Von Willebrand factor (vWf) and increased neutrophil to lymphocyte (N/L) ratio may reflect vascular inflammation in hypertensive patients. In present study, we aimed to investigate the effects of valsartan as an angiotensin II receptor antagonist and amlodipine as a calcium channel blocker on the vWf levels and N/L ratio in patients with essential hypertension. Patients were randomized to one of the following intervention protocols: calcium channel blocker (amlodipine, 5-10 mg/day) as group A (n = 20 mean age 51.85 +/- 11.32 y) and angiotensine II receptor blocker (valsartan, 80-320 mg/day) as group B (n = 26 mean age 49.12 +/- 14.12 y). Endothelial dysfunction and vascular inflammation were evaluated with vWf levels and N/L ratio in hypertensive patients before treatment and after treatment in the 12th week. No statistically significant differences were found among the groups in terms of age, sex, and body mass index (BMI). There was a significant decrease in vWf levels (P < .001) and N/L ratio after treatment (P = .04, P < .001, respectively) in both the groups. Von Willebrand factor levels and N/L ratio are very important markers having a role in vascular inflammation and antihypertensive treatment with amlodipine and valsartan may improve cardiovascular outcomes by decreasing these biomarkers.